港股異動 | 河北建設(01727.HK)大漲11%再度破頂 績後獲機構唱好
格隆匯8月26日丨河北建設(01727.HK)大漲11.06%再創新高,報15.66港元,暫成交1344萬港元,最新總市值275.8億港元。公司股價自5月以來,累計升幅高達230%。受疫情影響,河北建設上半年股東應占利潤2.49億元,同比下滑54.9%。大同投顧報告稱,公司上半年財報符合預期,與中鐵建合作充滿想象空間,上調評級至“強力買入”,上調目標價至每股25港元。手持的訂單同比增長6.4%至1,040億元人民幣,相當於公司未來兩年收入。預計疫情後下半年公司收入將實現報復性反彈,有望實現同比增長50%。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.